PMID- 11717621
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20071115
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 142
IP  - 6
DP  - 2001 Dec
TI  - Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe 
      heart failure.
PG  - E10
AB  - BACKGROUND: Insulin-like growth factor 1 (IGF-1) promotes favorable cardiac 
      remodeling in heart failure. However, the relation of plasma IGF-1 in patients 
      with various degrees of heart failure is not known. METHODS: Venous plasma 
      samples were collected from patients with clinically documented heart failure (n 
      = 24) and from control subjects (n = 21) for measurements of IGF-1 levels. In the 
      heart failure group, functional assessment of the physical capacity was 
      determined by means of the New York Heart Association (NYHA) score. Objective 
      determination of ventricular performance was made by transthoracic 
      echocardiographic measurement of left ventricular fractional shortening (FS). 
      RESULTS: IGF-1 levels were higher in patients with heart failure (mean age, 67 
      +/- 2 years; 17 men) than in control subjects (age, 71 +/- 2 years; 9 men) (20.2 
      +/- 2 mU/L, 14.1 +/- 2 mU/L, respectively, P <.05). However, the elevated IGF-1 
      levels were demonstrated only in patients with mild-to-moderate symptoms (NYHA 
      classes I and II) of heart failure (24.7 +/- 3.3 mU/L, n = 12, P =.005 vs control 
      subjects) but not in patients with severe symptoms (NYHA classes III and IV) 
      (15.7 +/- 2.3 mU/L, n = 12). There was a strong positive correlation between 
      IGF-1 levels and left ventricular FS (%) (r = 0.58, P =.003, n = 24). Adjustments 
      for other potential confounders including age, sex, treatment received, and 
      underlying cause of heart failure did not alter the relation between IGF-1 and 
      left ventricular FS (odds ratio, 2.01; 95% confidence interval, 1.26 to 6.24; P 
      =.01). CONCLUSIONS: Plasma levels of IGF-1 show distinct variations with the 
      severity of heart failure and may play a vital role in compensated heart failure.
FAU - Al-Obaidi, M K
AU  - Al-Obaidi MK
AD  - National Heart and Lung Institute, Department of Cardiology, Imperial College 
      School of Medicine, London, UK. m.al-obaidi@rbh.nthames.nhs.uk
FAU - Hon, J K
AU  - Hon JK
FAU - Stubbs, P J
AU  - Stubbs PJ
FAU - Barnes, J
AU  - Barnes J
FAU - Amersey, R A
AU  - Amersey RA
FAU - Dahdal, M
AU  - Dahdal M
FAU - Laycock, J F
AU  - Laycock JF
FAU - Noble, M I
AU  - Noble MI
FAU - Alaghband-Zadeh, J
AU  - Alaghband-Zadeh J
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Aged
MH  - Female
MH  - Heart Failure/*blood/*classification
MH  - Humans
MH  - Insulin-Like Growth Factor I/*analysis
MH  - Linear Models
MH  - Male
EDAT- 2001/11/22 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/22 10:00
PHST- 2001/11/22 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/22 10:00 [entrez]
AID - S0002-8703(01)22494-6 [pii]
AID - 10.1067/mhj.2001.118116 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Dec;142(6):E10. doi: 10.1067/mhj.2001.118116.